Shots:

• The approval follows P-III ACE study assessing chidamide + exemestane demonstrated PFS benefit and the includes Chidamide + aromatase inhibitor in postmenopausal patients with HR+- HER2- advanced breast cancer (ABC) treated with endocrine therapies for recurrence or progression
• Chidamide (CS055/HBI-8000/tucidinostat) is an orally available low-nanomolar inhibitor of cancer-associated histone deacetylase (HDAC) enzymes targeting subtype 1- 2- 3 of Class I and subtype 10 of Class IIb HDAC and has also received CFDA approval for recurrent and refractory peripheral T-cell lymphoma in Dec 2014  
• Epidaza is currently being evaluated as monothx or in combination with chemotherapeutic/targeted agents for the treatment of various hematological tumors- solid cancers- and HIV in the United States- Japan- Korea- China- and Taiwan

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaworld